A Phase 2 interventional study of PRV-015 and Placebo in Celiac Disease, sponsored by Provention Bio, a Sanofi Company. Completed at 38 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-10-20.
Sponsored by Provention Bio, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.
Among the 103 studies in Celiac Disease with a site in United States, this one is the 3rd largest by enrollment of the 68 interventional ones that give a count, is one of 7 that started in 2020, is one of 21 in phase 2, and was the 70th registered.
353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.
Browse Celiac Disease studies →16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:
Nielsen Fernandez-Becker · Sites in United States
Ages 18+
Chugai Pharmaceutical · Sites in United States, Australia, New Zealand
Ages 18–75
Joined Bio · Sites in United States
Ages 18–90 · Healthy volunteers
Columbia University · Sites in United States
Ages 18–75
Luventix, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 22 · Phase 3 2 · Phase 4 2
First in 1995; this study’s year is marked. 7 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 388 is above the median of 50 across 215 interventional studies indexed under Celiac Disease.
Median enrollment 46 across the 68 interventional studies, 175 across the 35 observational. Of the 74 that completed or were terminated, 17 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 103 have an industry lead sponsor. The 10 most frequent:
This study is registered under Provention Bio, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Provention Bio, a Sanofi Company is the lead sponsor of 4 studies on the registry; none are open to participants now.
Sanofi has 2 studies filed under Celiac Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Celiac Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06310291Barinthus BiotherapeuticsVTP-1000 in Adults With Celiac Disease | 2026-11 |
| NCT06908057AdventHealth Translational Research InstituteAccessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D) | 2026-12 |
| NCT05680012University of ChicagoTissue Destruction and Healing in Celiac Disease | 2027-05-01 |
| NCT07377565Nielsen Fernandez-BeckerA First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease | 2027-06-01 |
| NCT07239336Chugai PharmaceuticalStudy of DONQ52 in Active Celiac Disease | 2027-06-15 |
Add all 7 to your calendar (.ics) → With an account.
Among the 103 studies in Celiac Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of PRV-015 in adult patients with non-responsive celiac disease (NRCD) who are on a gluten-free diet (GFD).
PRV-015-002b is a Phase 2b, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 3 dose regimens of PRV-015 in adult patients with NRCD who are on a GFD.
Eligible subjects include male or female adults, 18 to 70 years of age, with a diagnosis of celiac disease and have followed a GFD for at least 12 consecutive months, yet continue to experience symptoms.
Study drug (1 of the 3 doses of PRV-015 or placebo) will be administered in a double-blind fashion, followed by a safety follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PRV-015 Low Dose, sterile solution for subcutaneous administration
Biological: PRV-015
PRV-015 Medium Dose, sterile solution for subcutaneous administration
Biological: PRV-015
PRV-015 High Dose, sterile solution for subcutaneous administration
Biological: PRV-015
Placebo, sterile solution for subcutaneous administration
Other: Placebo
Fully human monoclonal antibody against interleukin 15 (IL-15)
Placebo
Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24
The CeD PRO questionnaire was captured daily in the eDiary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Abdominal Symptoms domain included abdominal cramping, abdominal pain, bloating and gas. Total score for abdominal symptoms domain range from 0 to 40. Higher scores indicated worse outcome. Baseline abdominal symptoms domain score was defined as the average of the daily scores for the last week of the placebo run-in period.
Time frame: Baseline (average of Day -7 to Day -1) up to Week 24
Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Diarrhea and Loose Stool Domain Score Through Week 24
The CeD PRO questionnaire was captured daily in the eDiary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Diarrhea and loose stool domain included diarrhea and loose stool. Total score for diarrhea and loose stool domain range from 0 to 20. Higher scores indicated worse outcome. Baseline diarrhea and loose stool domain score was defined as the average of the daily scores for the last week of the placebo run-in period.
Time frame: Baseline (average of Day -7 to Day -1) up to Week 24
Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Total Gastrointestinal (GI) Score Through Week 24
The CeD PRO questionnaire was captured daily in the eDiary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Total GI domain included abdominal symptoms domain, diarrhea, loose stool and nausea. Total GI score range from 0 to 70. Higher scores indicated worse outcome. Baseline GI score was defined as the average of the daily scores for the last week of the placebo run-in period.
Time frame: Baseline (average of Day -7 to Day -1) up to Week 24
Absolute Change From Baseline in Intraepithelial Lymphocyte (IEL) Density at Week 24
The small intestinal mucosal inflammation was measured by IEL density using immunohistochemistry. Baseline was defined as IEL density from the esophagogastroduodenoscopy biopsy conducted during the run-in period.
Time frame: Baseline to Week 24
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events of Special Interest (AESIs)
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE was defined as any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. AESIs included severe opportunistic infections and hypersensitivity reactions of at least moderate severity. A TEAE was defined as an AE that occurred from the first dose of post-randomization study drug administration through the end of the study.
Time frame: From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days
Number of Participants With Potentially Clinically Important Changes in Hematology
Blood samples were collected to determine the hematology laboratory important changes. CHG= Change from baseline hemoglobin.
Time frame: From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days
Number of Participants With Potentially Clinically Important Changes in Clinical Chemistry
Blood samples were collected to determine the clinical chemistry laboratory important changes. ULN= Upper limit of normal, mmol/L= millimoles per liter and mcmol/L= micromoles per liter.
Time frame: From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days
Number of Participants With Potentially Clinically Important Changes in Urinalysis
Urine samples were collected to determine the important changes in urine. TNTC= Too numerous to count, LPF= Low power field and HPF= High power field.
Time frame: From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days
Number of Participants With Potentially Clinically Important Changes in Vital Signs and Body Weight
Participant's vital signs and body weight were examined to determine the important changes. Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate. mmHg= millimeters of mercury, DFB= Decrease from baseline and IFB= Increase from baseline.
Time frame: From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days
Number of Participants With Anti-PRV-015 Antibodies
Blood samples were collected to determine the presence of anti-drug antibodies by immunoassay.
Time frame: Baseline (Day 1) and Weeks 2, 4, 12, 22, 24 and 28
Minimum Serum Concentrations (Cmin) of PRV-015
Blood samples were collected at specified timepoints to determine the Cmin.
Time frame: Pre-dose on Day 1 and Weeks 2, 4, 8, 12, 16, 20, 22, 24 and 28
The study was conducted at 39 centers in 4 countries. A total of 648 participants were screened between 24 August 2020 and 16 January 2024, of which 255 participants were screen failures and 5 participants discontinued before run-in period. Screen failures were mainly due to not meeting eligibility criteria.
| Milestone | Single-blind: Placebo | Double-blind: Placebo | Double-blind: PRV-015 100 mg | Double-blind: PRV-015 300 mg | Double-blind: PRV-015 600 mg |
|---|---|---|---|---|---|
| Started | 388 | 0 | 0 | 0 | 0 |
| Received treatment | 387 | 0 | 0 | 0 | 0 |
| Completed | 352 | 0 | 0 | 0 | 0 |
| Not completed | 36 | 0 | 0 | 0 | 0 |
| Withdrew: Not treated | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Run-in failure | 27 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator or sponsor judgement | 1 | 0 | 0 | 0 | 0 |
| Milestone | Single-blind: Placebo | Double-blind: Placebo | Double-blind: PRV-015 100 mg | Double-blind: PRV-015 300 mg | Double-blind: PRV-015 600 mg |
|---|---|---|---|---|---|
| Started | 0 | 57 | 56 | 57 | 56 |
| Received treatment | 0 | 57 | 56 | 57 | 54 |
| Completed | 0 | 51 | 47 | 51 | 49 |
| Not completed | 0 | 6 | 9 | 6 | 7 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 5 | 5 | 6 |
| Withdrew: Investigator or sponsor judgement | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 1 | 3 | 1 | 0 |
The CeD PRO questionnaire was captured daily in the eDiary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Abdominal Symptoms domain included abdominal cramping, abdominal pain, bloating and gas. Total score for abdominal symptoms domain range from 0 to 40. Higher scores indicated worse outcome. Baseline abdominal symptoms domain score was defined as the average of the daily scores for the last week of the placebo run-in period.
| score on a scale | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|---|---|---|---|---|
| Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24 | -1.32 (-1.66 to -0.98) | -1.28 (-1.62 to -0.94) | -1.21 (-1.55 to -0.88) | -1.28 (-1.63 to -0.93) |
The CeD PRO questionnaire was captured daily in the eDiary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Diarrhea and loose stool domain included diarrhea and loose stool. Total score for diarrhea and loose stool domain range from 0 to 20. Higher scores indicated worse outcome. Baseline diarrhea and loose stool domain score was defined as the average of the daily scores for the last week of the placebo run-in period.
| score on a scale | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|---|---|---|---|---|
| Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Diarrhea and Loose Stool Domain Score Through Week 24 | -0.77 (-1.15 to -0.40) | -0.66 (-1.04 to -0.28) | -1.02 (-1.39 to -0.64) | -1.07 (-1.46 to -0.68) |
The CeD PRO questionnaire was captured daily in the eDiary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Total GI domain included abdominal symptoms domain, diarrhea, loose stool and nausea. Total GI score range from 0 to 70. Higher scores indicated worse outcome. Baseline GI score was defined as the average of the daily scores for the last week of the placebo run-in period.
| score on a scale | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|---|---|---|---|---|
| Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Total Gastrointestinal (GI) Score Through Week 24 | -0.89 (-1.15 to -0.63) | -0.84 (-1.10 to -0.57) | -0.88 (-1.14 to -0.62) | -1.05 (-1.32 to -0.78) |
The small intestinal mucosal inflammation was measured by IEL density using immunohistochemistry. Baseline was defined as IEL density from the esophagogastroduodenoscopy biopsy conducted during the run-in period.
| cells/100 epithelial cells | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|---|---|---|---|---|
| Absolute Change From Baseline in Intraepithelial Lymphocyte (IEL) Density at Week 24 | -0.39 (-3.82 to 3.03) | 1.54 (-1.99 to 5.07) | -4.11 (-7.56 to -0.66) | -4.53 (-8.13 to -0.93) |
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE was defined as any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. AESIs included severe opportunistic infections and hypersensitivity reactions of at least moderate severity. A TEAE was defined as an AE that occurred from the first dose of post-randomization study drug administration through the end of the study.
| Participants | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|---|---|---|---|---|
| Any TEAE | 34 | 34 | 36 | 29 |
| TEAE leading to study treatment discontinuation | 1 | 1 | 2 | 0 |
| Treatment-emergent SAE | 1 | 0 | 0 | 1 |
| Treatment-emergent AESI | 2 | 1 | 1 | 1 |
Blood samples were collected to determine the hematology laboratory important changes. CHG= Change from baseline hemoglobin.
| Participants | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|---|---|---|---|---|
| Hemoglobin: CHG <=-20 g/L | 0 | 0 | 1 | 2 |
| Neutrophils: <1 10^9/L | 2 | 1 | 4 | 2 |
Blood samples were collected to determine the clinical chemistry laboratory important changes. ULN= Upper limit of normal, mmol/L= millimoles per liter and mcmol/L= micromoles per liter.
| Participants | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|---|---|---|---|---|
| Alanine Aminotransferase: >=3x ULN | 1 | 4 | 1 | 2 |
| Aspartate Aminotransferase: >=3x ULN | 1 | 2 | 0 | 0 |
| Chloride: >125 mmol/L | 1 | 0 | 1 | 0 |
| Creatinine: >=132 mcmol/L | 1 | 1 | 0 | 0 |
| Potassium: >6 mmol/L | 0 | 0 | 2 | 1 |
| Sodium: <125 mmol/L | 0 | 0 | 1 | 0 |
Urine samples were collected to determine the important changes in urine. TNTC= Too numerous to count, LPF= Low power field and HPF= High power field.
| Participants | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|---|---|---|---|---|
| Bacteria: Present | 54 | 51 | 55 | 47 |
| Crystals: Present | 3 | 4 | 2 | 5 |
| Erythrocytes (/HPF): Many/TNTC | 1 | 0 | 4 | 3 |
| Glucose: 3+/4+ | 1 | 2 | 1 | 0 |
| Hyaline Casts (/HPF): Few/Moderate/Many | 3 | 2 | 3 | 0 |
| Hyaline Casts (/LPF): Few/Moderate/Many | — | 1 | 1 | — |
| Ketones: 3+ | 1 | 2 | 3 | 1 |
| Leukocyte Esterase: 3+/4+ | 19 | 12 | 16 | 15 |
| Leukocytes (/HPF): Many/TNTC | 11 | 3 | 9 | 7 |
| Nitrite: Positive | 2 | 1 | 2 | 1 |
| Squamous Epithelial Cells (/HPF): Many/TNTC | 6 | 0 | 6 | 8 |
Participant's vital signs and body weight were examined to determine the important changes. Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate. mmHg= millimeters of mercury, DFB= Decrease from baseline and IFB= Increase from baseline.
| Participants | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|---|---|---|---|---|
| SBP: <=95 mmHg and DFB >=20 mmHg | 5 | 2 | 6 | 1 |
| SBP: >=160 mmHg and IFB >=20 mmHg | 2 | 1 | 0 | 1 |
| DBP: >=110 mmHg and IFB >=10 mmHg | 0 | 0 | 0 | 1 |
| Heart Rate: <=50 bpm and DFB >=20 bpm | 1 | 1 | 1 | 0 |
| Heart Rate: >=120 bpm and IFB >=20 bpm | 0 | 0 | 0 | 1 |
| Body weight: >=5% DFB | 8 | 11 | 9 | 7 |
| Body weight: >=5% IFB | 9 | 8 | 13 | 5 |
Blood samples were collected to determine the presence of anti-drug antibodies by immunoassay.
| Participants | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|---|---|---|---|
| Baseline | 3 | 8 | 7 |
| Week 2 | 8 | 9 | 9 |
| Week 4 | 5 | 6 | 5 |
| Week 12 | 4 | 5 | 4 |
| Week 22 | 4 | 4 | 2 |
| Week 24 | 4 | 3 | 2 |
| Week 28 | 4 | 3 | 2 |
Blood samples were collected at specified timepoints to determine the Cmin.
| nanogram per milliliter | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|---|---|---|---|
| Week 2 | 8778 ± 74.1 | 27820 ± 39.8 | 66400 ± 46.1 |
| Week 4 | 15140 ± 42.8 | 51190 ± 42.1 | 98420 ± 49.4 |
| Week 8 | 21790 ± 46.4 | 61990 ± 66.5 | 142600 ± 43.7 |
| Week 12 | 23630 ± 46.8 | 73150 ± 56.5 | 168300 ± 37.9 |
| Week 16 | 22960 ± 46.7 | 75830 ± 65.1 | 166700 ± 44.9 |
| Week 20 | 27000 ± 42.5 | 74110 ± 67.8 | 186400 ± 51.2 |
| Week 22 | 25410 ± 36.2 | 73120 ± 64.2 | 181000 ± 55.6 |
| Week 24 | 26680 ± 40.3 | 72400 ± 49.6 | 160500 ± 47.5 |
| Week 28 | 10210 ± 58.0 | 32810 ± 80.0 | 69370 ± 78.3 |
Collected over Single-blind Period: From first dose of study drug administration (Day 1) up to 28 days. Double-blind Period: From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single-blind: Placebo | 0/387 (0%) | 2/387 (0.5%) | 0/387 (0%) |
| Double-blind: Placebo | 0/57 (0%) | 1/57 (1.8%) | 22/57 (38.6%) |
| Double-blind: PRV-015 100 mg | 0/56 (0%) | 0/56 (0%) | 18/56 (32.1%) |
| Double-blind: PRV-015 300 mg | 0/57 (0%) | 0/57 (0%) | 22/57 (38.6%) |
| Double-blind: PRV-015 600 mg | 0/54 (0%) | 1/54 (1.9%) | 19/54 (35.2%) |
| Event | Single-blind: Placebo | Double-blind: Placebo | Double-blind: PRV-015 100 mg | Double-blind: PRV-015 300 mg | Double-blind: PRV-015 600 mg |
|---|---|---|---|---|---|
| PresyncopeNervous system disorders | 0/387 | 0/57 | 0/56 | 0/57 | 1/54 |
| Pelvic FractureInjury, poisoning and procedural complications | 0/387 | 1/57 | 0/56 | 0/57 | 0/54 |
| Gluten SensitivityMetabolism and nutrition disorders | 1/387 | 0/57 | 0/56 | 0/57 | 0/54 |
| IntussusceptionGastrointestinal disorders | 1/387 | 0/57 | 0/56 | 0/57 | 0/54 |
| Event | Single-blind: Placebo | Double-blind: Placebo | Double-blind: PRV-015 100 mg | Double-blind: PRV-015 300 mg | Double-blind: PRV-015 600 mg |
|---|---|---|---|---|---|
| Covid-19Infections and infestations | 0/387 | 3/57 | 5/56 | 8/57 | 5/54 |
| DiarrhoeaGastrointestinal disorders | 0/387 | 6/57 | 1/56 | 4/57 | 4/54 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/387 | 5/57 | 3/56 | 4/57 | 4/54 |
| HeadacheNervous system disorders | 0/387 | 1/57 | 4/56 | 5/57 | 2/54 |
| NauseaGastrointestinal disorders | 0/387 | 1/57 | 2/56 | 5/57 | 3/54 |
| Abdominal PainGastrointestinal disorders | 0/387 | 3/57 | 3/56 | 0/57 | 4/54 |
| MigraineNervous system disorders | 0/387 | 4/57 | 2/56 | 1/57 | 1/54 |
| RashSkin and subcutaneous tissue disorders | 0/387 | 4/57 | 0/56 | 3/57 | 1/54 |
| Injection Site BruisingGeneral disorders | 0/387 | 0/57 | 0/56 | 2/57 | 3/54 |
| Injection Site ReactionGeneral disorders | 0/387 | 1/57 | 3/56 | 3/57 | 3/54 |
Single-blind period: Participants treated with single-blind placebo in run-in period are included. Double-blind period: The intent-to-treat analysis set included all randomized participants.
| Age, Continuous(years) | Single-blind: Placebo | Double-blind: Placebo | Double-blind: PRV-015 100 mg | Double-blind: PRV-015 300 mg | Double-blind: PRV-015 600 mg | Total |
|---|---|---|---|---|---|---|
| Single-blind period | 41.2 ± 13.8 | — | — | — | — | 41.2 ± 13.8 |
| Double-blind period | — | 41.0 ± 14.53 | 41.9 ± 14.82 | 39.0 ± 12.25 | 37.9 ± 12.58 | 39.9 ± 13.59 |
| Sex: Female, Male(Participants) | Single-blind: Placebo | Double-blind: Placebo | Double-blind: PRV-015 100 mg | Double-blind: PRV-015 300 mg | Double-blind: PRV-015 600 mg | Total |
|---|---|---|---|---|---|---|
| Single-blind period — Female | 313 | 0 | 0 | 0 | 0 | 313 |
| Single-blind period — Male | 74 | 0 | 0 | 0 | 0 | 74 |
| Double-blind period — Female | 0 | 53 | 38 | 50 | 45 | 186 |
| Double-blind period — Male | 0 | 4 | 18 | 7 | 11 | 40 |
| Race/Ethnicity, Customized(Participants) | Single-blind: Placebo | Double-blind: Placebo | Double-blind: PRV-015 100 mg | Double-blind: PRV-015 300 mg | Double-blind: PRV-015 600 mg | Total |
|---|---|---|---|---|---|---|
| Single-blind period — Black or African American | 4 | — | — | — | — | 4 |
| Single-blind period — White | 375 | — | — | — | — | 375 |
| Single-blind period — Asian | 1 | — | — | — | — | 1 |
| Single-blind period — American Indian or Alaska Native | 2 | — | — | — | — | 2 |
| Single-blind period — Not Reported | 3 | — | — | — | — | 3 |
| Single-blind period — Unknown | 1 | — | — | — | — | 1 |
| Single-blind period — Multiple | 1 | — | — | — | — | 1 |
| Double-blind period — Black or African American | — | 0 | 1 | 0 | 0 | 1 |
| Double-blind period — White | — | 57 | 55 | 56 | 53 | 221 |
| Double-blind period — Asian | — | 0 | 0 | 0 | 0 | 0 |
| Double-blind period — American Indian or Alaska Native | — | 0 | 0 | 0 | 0 | 0 |
| Double-blind period — Not Reported | — | 0 | 0 | 0 | 2 | 2 |
| Double-blind period — Unknown | — | 0 | 0 | 0 | 1 | 1 |
| Double-blind period — Multiple | — | 0 | 0 | 1 | 0 | 1 |
| Celiac Disease Patient Reported Outcome (CeD PRO) Abdominal Symptoms Domain Score(Participants) | Single-blind: Placebo | Double-blind: Placebo | Double-blind: PRV-015 100 mg | Double-blind: PRV-015 300 mg | Double-blind: PRV-015 600 mg | Total |
|---|---|---|---|---|---|---|
| Single-blind period — Score: <3 | — | — | — | — | — | 0 |
| Single-blind period — Score: >=3 | — | — | — | — | — | 0 |
| Double-blind period — Score: <3 | — | 13 | 13 | 13 | 13 | 52 |
| Double-blind period — Score: >=3 | — | 44 | 43 | 44 | 43 | 174 |
| Number of Participants for Stratification Factor Villous Height-to-Crypt Depth Ratio (VH:CD)(Participants) | Single-blind: Placebo | Double-blind: Placebo | Double-blind: PRV-015 100 mg | Double-blind: PRV-015 300 mg | Double-blind: PRV-015 600 mg | Total |
|---|---|---|---|---|---|---|
| Single-blind period — Ratio: <2 | — | — | — | — | — | 0 |
| Single-blind period — Ratio: >=2 | — | — | — | — | — | 0 |
| Double-blind period — Ratio: <2 | — | 37 | 37 | 37 | 36 | 147 |
| Double-blind period — Ratio: >=2 | — | 20 | 19 | 20 | 20 | 79 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Aug 2020 to primary completion in Jul 2024, 47 months.
Results were first posted in Oct 2025, 1 year 2 months after primary completion.
Of 24 phase 2 interventional studies under Celiac Disease, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's 47 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AMG-714